MARKET

BPTH

BPTH

Bio Path Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.600
-0.120
-2.54%
Closed 16:00 04/07 EDT
OPEN
4.800
PREV CLOSE
4.720
HIGH
4.963
LOW
4.545
VOLUME
46.65K
TURNOVER
--
52 WEEK HIGH
24.73
52 WEEK LOW
2.920
MARKET CAP
16.98M
P/E (TTM)
-1.4018
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BPTH stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.

EPS

BPTH News

More
  • GRPN, TOPS, NCLH and BGCP among midday movers
  • Seeking Alpha - Article · 03/27 16:41
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Edited Transcript of BPTH earnings conference call or presentation 6-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/13 20:59
  • Bio-Path Holdings Appoints Ernst & Young as New Auditor
  • GlobeNewswire · 03/11 11:00

Industry

Biotechnology & Medical Research
-2.89%
Pharmaceuticals & Medical Research
-0.82%

Hot Stocks

Symbol
Price
%Change

About BPTH

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
More

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.